Gilead Sciences · 3 days ago
Director, US Virology Strategy and Policy - Government Affairs
United States - District of Columbia - Washington
Full-time
Hybrid
Director/Executive
$206K/yr - $266K/yr
10+ years expGilead Sciences is dedicated to creating a healthier world by developing therapies for life-threatening illnesses. The Director of US Virology Strategy and Policy will lead projects to shape public policy related to virology, focusing on HIV, and will work collaboratively with various teams to advocate for patient access to innovative treatments.
BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Report to ED of Virology Strategy and Policy and will be a member of the virology strategy and policy team
Support and help manage the annual strategic planning process, resulting in comprehensive government affairs strategies that shape the US public policy environment for existing and pipeline products in virology, primarily HIV
Collaborate with members of across GA teams to define and evolve Gilead’s U.S. virology policy positions in support of corporate mission to maintain patient-provider choice and access to innovative HIV treatment and prevention medicines
Support the execution of these strategies by GA organization and collaborate with cross-functional partners on key workstreams
Anticipate trends in the external environment that will impact HIV markets and develop plans to address areas of concern
Develop resources for internal and external stakeholders, including talking points, issue briefs, one-pagers, reports and presentations, that outline policy positions, implications, arguments and key messages
Support engagement with influential third-party policy organizations, including health care policy experts, policy research organizations, and aligned patient advocacy groups
Qualification
Required
Twelve years of experience with a Bachelor's degree in related field or ten years with a master's degree with relevant public or private sector experience in health care industry, or combination of experience and related advanced degree (MPH, MPP, MBA, PhD)
Deep understanding of U.S. government policies that impact the pharmaceutical industry; experience in HIV policy and/or infectious diseases policy preferred
Demonstrated proficiency in policy-related strategy, analytics, communication, presentation and problem solving
Experience delivering policy initiatives with demonstrated success
Exceptional organizational and project management skills – demonstrated ability to independently manage multiple work streams
Excellent verbal, analytical, written and interpersonal communications skills, particularly in interpreting complex technical rhetoric for general audience. English fluency required
Demonstrated experience working collaboratively with internal and external partners
Demonstrated experience managing strategy workshops and developing strategic documents, briefing documents and presentations. Strategy consulting training and/or experience preferred
Domestic travel [25%] required
Preferred
Deep understanding of U.S. government policies that impact the pharmaceutical industry; experience in HIV policy and/or infectious diseases policy preferred
Strategy consulting training and/or experience preferred
Benefits
Discretionary annual bonus
Discretionary stock-based long-term incentives (eligibility may vary based on role)
Paid time off
Company-sponsored medical, dental, vision, and life insurance plans
Company
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
10001+ employees
H1B Sponsorship
Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (269)
2024 (241)
2023 (222)
2022 (208)
2021 (235)
2020 (187)
Funding
Current Stage
Public CompanyTotal Funding
$4.41BKey Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B
Leadership Team
Keeley Wettan
Senior Vice President, Legal
Patrick Loerch
Senior Vice President, Clinical Data Science
Recent News
2026-01-09
2026-01-08
2026-01-07
Company data provided by crunchbase